Indication
for treating relapsed or refractory diffuse large B-cell non-Hodgkin lymphoma

Medicine details

Medicine name:
axicabtagene ciloleucel (Yescarta)
SMC ID:
SMC2114
Pharmaceutical company
Kite Pharma, a Gilead Company
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Advice due date:
11 February 2019
SMC meeting date:
06 November 2018
Patient group submission deadline:
03 September 2018